ESC Premium Access

Controversies in antithrombotic treatment for primary and secondary prevention

Event: ESC CONGRESS 2019
Topic: Cardiovascular Pharmacotherapy
Session type: Debate Session
Date: 3 September 2019
Time: 11:00 - 12:30

Session

6 presentations in this session

Aspirin is out for primary prevention of cardiovascular disease - PRO.

Speaker: Professor J. Armitage (Oxford, GB)
Thumbnail

Aspirin is out for primary prevention of cardiovascular disease - CON.

Speaker: Professor C. Patrono (Rome, IT)
Thumbnail

Aspirin is out for primary prevention of cardiovascular disease - Discussion.

Thumbnail

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - PRO.

Speaker: Doctor J. Eikelboom (Hamilton, CA)
Thumbnail

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - CON.

Speaker: Doctor T. Cuisset (Marseille, FR)
Thumbnail

All patients with atherosclerotic disease should receive long-term intensified antithrombotic treatment beyond aspirin for secondary prevention - Discussion.

Thumbnail

4 speakers from this session

Professor Jane Armitage

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)
10 presentations
1 follower

Professor Carlo Patrono

Catholic University of the Sacred Heart, Rome (Italy)
4 presentations
0 follower

Doctor John William Eikelboom

McMaster University, Hamilton (Canada)
32 presentations
0 follower

Doctor Thomas Cuisset

AP-HM - Hospital La Timone, Marseille (France)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk